Stalfate is a locally acting substance that in an acidic environment (pH < 40) reacts with hydrochloric acid in the stomach to form a cross-linking, viscous, paste-like material capable of acting as an acid buffer for as long as 6 to 8 hours after a single dose. These complexes serve as protective barriers at the ulcer surface, preventing further damage from acid, pepsin, and bile. Stalfate also stimulates the increase of prostaglandin E2, epidermal growth factors(EGF), bFGF, and gastric mucus.
After oral administration, the sucralfate in Stalfate reacts with hydrochloric acid in the stomach to form a paste-like complex that will bind to the proteinaceous exudates that generally are found at ulcer sites. This insoluble complex forms a barrier at the site and protects the ulcer from further damage caused by pepsin, acid or bile.
Triple combination therapy with lansoprazole+ cisapride+ sucralfate can significantly improve symptoms and quality of life and was more cost-effective than ranitidine combination group.
Aphthous ulcer and stomatitis due to radiation or chemotherapy.
Gastro esophagal reflux disease during pregnancy : first line drug therapy combined with life style and diet modification.